These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34320390)

  • 21. Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine.
    Chen LL; Chua GT; Lu L; Chan BP; Wong JS; Chow CC; Yu TC; Leung AS; Lam SY; Wong TW; Tsang HW; Wong IC; Chan KH; Yuen KY; Ip P; Kwan MY; To KK
    Emerg Microbes Infect; 2022 Dec; 11(1):543-547. PubMed ID: 35084295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
    Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
    BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant.
    Gruell H; Vanshylla K; Tober-Lau P; Hillus D; Schommers P; Lehmann C; Kurth F; Sander LE; Klein F
    Nat Med; 2022 Mar; 28(3):477-480. PubMed ID: 35046572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections.
    Kurahashi Y; Sutandhio S; Furukawa K; Tjan LH; Iwata S; Sano S; Tohma Y; Ohkita H; Nakamura S; Nishimura M; Arii J; Kiriu T; Yamamoto M; Nagano T; Nishimura Y; Mori Y
    Front Immunol; 2022; 13():773652. PubMed ID: 35281007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies.
    Tada T; Dcosta BM; Samanovic-Golden M; Herati RS; Cornelius A; Mulligan MJ; Landau NR
    bioRxiv; 2021 Feb; ():. PubMed ID: 33564768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutralizing antibodies from naturally infected individuals against SARS-CoV-2 Gamma and Delta variants in the Paraguayan population.
    Samudio A; Sotelo PH; González-Maldonado P; Alfonso L; Valiente-Echeverría F; Soto-Rifo R; Langjahr P
    J Infect Dev Ctries; 2023 Oct; 17(10):1407-1412. PubMed ID: 37956377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low Neutralizing Antibody Titers against the Mu Variant of SARS-CoV-2 in 31 BNT162b2 Vaccinated Individuals in Colombia.
    Álvarez-Díaz DA; Muñoz AL; Tavera-Rodríguez P; Herrera-Sepúlveda MT; Ruiz-Moreno HA; Laiton-Donato K; Franco-Muñoz C; Pelaez-Carvajal D; Cuellar D; Muñoz-Suarez AM; Galindo M; Arias-Ramírez EJ; Mercado-Reyes M
    Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex.
    Tang J; Grubbs G; Lee Y; Huang C; Ravichandran S; Forgacs D; Golding H; Ross TM; Khurana S
    EBioMedicine; 2021 Dec; 74():103748. PubMed ID: 34902788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.
    Muik A; Wallisch AK; Sänger B; Swanson KA; Mühl J; Chen W; Cai H; Maurus D; Sarkar R; Türeci Ö; Dormitzer PR; Şahin U
    Science; 2021 Mar; 371(6534):1152-1153. PubMed ID: 33514629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.
    Fernández J; Bruneau N; Fasce R; Martín HS; Balanda M; Bustos P; Ulloa S; Mora J; Ramírez E
    J Med Virol; 2022 Jan; 94(1):399-403. PubMed ID: 34460119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
    Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
    EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study.
    Olariu TR; Ursoniu S; Marincu I; Lupu MA
    Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946275
    [No Abstract]   [Full Text] [Related]  

  • 35. Characterization of a new SARS-CoV-2 variant that emerged in Brazil.
    Imai M; Halfmann PJ; Yamayoshi S; Iwatsuki-Horimoto K; Chiba S; Watanabe T; Nakajima N; Ito M; Kuroda M; Kiso M; Maemura T; Takahashi K; Loeber S; Hatta M; Koga M; Nagai H; Yamamoto S; Saito M; Adachi E; Akasaka O; Nakamura M; Nakachi I; Ogura T; Baba R; Fujita K; Ochi J; Mitamura K; Kato H; Nakajima H; Yagi K; Hattori SI; Maeda K; Suzuki T; Miyazato Y; Valdez R; Gherasim C; Furusawa Y; Okuda M; Ujie M; Lopes TJS; Yasuhara A; Ueki H; Sakai-Tagawa Y; Eisfeld AJ; Baczenas JJ; Baker DA; O'Connor SL; O'Connor DH; Fukushi S; Fujimoto T; Kuroda Y; Gordon A; Maeda K; Ohmagari N; Sugaya N; Yotsuyanagi H; Mitsuya H; Suzuki T; Kawaoka Y
    Proc Natl Acad Sci U S A; 2021 Jul; 118(27):. PubMed ID: 34140350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralization activity of sera/IgG preparations from fully BNT162b2 vaccinated individuals against SARS-CoV-2 Alpha, Beta, Gamma, Delta, and Kappa variants.
    Amano M; Otsu S; Maeda K; Uemura Y; Shimizu Y; Omata K; Matsuoka M; Shimada S; Mitsuya H
    Sci Rep; 2022 Aug; 12(1):13524. PubMed ID: 35941265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant.
    Edara VV; Lai L; Sahoo MK; Floyd K; Sibai M; Solis D; Flowers MW; Hussaini L; Ciric CR; Bechnack S; Stephens K; Mokhtari EB; Mudvari P; Creanga A; Pegu A; Derrien-Colemyn A; Henry AR; Gagne M; Graham BS; Wrammert J; Douek DC; Boritz E; Pinsky BA; Suthar MS
    bioRxiv; 2021 May; ():. PubMed ID: 34013272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants.
    Andreano E; Paciello I; Piccini G; Manganaro N; Pileri P; Hyseni I; Leonardi M; Pantano E; Abbiento V; Benincasa L; Giglioli G; De Santi C; Fabbiani M; Rancan I; Tumbarello M; Montagnani F; Sala C; Montomoli E; Rappuoli R
    Nature; 2021 Dec; 600(7889):530-535. PubMed ID: 34670266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera.
    Hu J; Wei XY; Xiang J; Peng P; Xu FL; Wu K; Luo FY; Jin AS; Fang L; Liu BZ; Wang K; Tang N; Huang AL
    Genes Dis; 2022 Sep; 9(5):1290-1300. PubMed ID: 34877393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.